Semaglutide ameliorates alcohol withdrawal anxiety in mice by restoring prefrontal cortex mitochondrial quality control
Background
Alcohol use disorder (AUD) affects approximately 280 million people globally, with withdrawal symptoms like anxiety being a major driver of relapse. Current medications for AUD are limited in number and efficacy, highlighting an urgent need for novel treatments. While neuronal damage is implicated in withdrawal-induced anxiety, the precise molecular mechanisms remain poorly understood. Agonists of the glucagon-like peptide-1 receptor (GLP-1R), such as semaglutide, have shown promise in various neurological contexts, making the GLP-1R pathway a compelling target for addressing the neuronal dysfunction underlying AUD.
Study Design
Researchers established a mouse model of alcohol withdrawal by exposing mice to 3 months of chronic ethanol exposure (CEE), followed by a withdrawal period. During withdrawal, mice were treated with semaglutide (0.03 mg/kg) via intraperitoneal (IP) injection. The study employed a multi-modal approach, including behavioral tests to assess anxiety-like behaviors, biochemical analyses to evaluate molecular changes, and morphological analyses to examine neuronal structures and mitochondrial health.
Results
Activation of GLP-1R with semaglutide significantly alleviated anxiety-like behaviors in mice subjected to CEE withdrawal. The study revealed that semaglutide treatment reversed the downregulation of GLP-1R and its downstream effector CREB specifically within the mitochondria of prefrontal cortex (PFC) neurons. This enhancement of the GLP-1R/CREB pathway was found to be crucial for regulating neuronal mitochondrial quality control. This included processes such as mitochondrial fission, fusion, and mitophagy, all vital for maintaining cellular energy and health. Ultimately, these actions led to the preservation of mitochondrial function and the amelioration of synaptic impairment, which are critical for normal brain function.
Semaglutide reversed the downregulation of
GLP-1RandCREBin prefrontal cortex neuronal mitochondria, restoring mitochondrial quality control and ameliorating synaptic impairment.
Key Findings
- Semaglutide alleviates anxiety-like behaviors in mice undergoing alcohol withdrawal.
- It reverses the downregulation of
GLP-1RandCREBin prefrontal cortex neuronal mitochondria. - Activation of the
GLP-1R/CREBpathway regulates mitochondrial quality control (fission, fusion, mitophagy). - Semaglutide maintains mitochondrial function and ameliorates synaptic impairment in withdrawal mice.
Why It Matters
This research identifies a novel mechanism by which GLP-1R activation, specifically with semaglutide, could offer a therapeutic avenue for alcohol withdrawal-induced anxiety. Given the high rates of relapse driven by anxiety in AUD, a treatment that targets neuronal mitochondrial health could significantly improve patient outcomes. The findings suggest that semaglutide, an already approved drug for diabetes and obesity, could be repurposed to address a critical unmet need in AUD management. While this is a preclinical animal study, the clear mechanistic insights into mitochondrial quality control provide a strong foundation for future translational research, potentially leading to human clinical trials exploring semaglutide's efficacy in AUD.
semaglutide
alcohol use disorder
aud
anxiety
glp-1r agonist
preclinical-animal